Wave Neuroscience is proud to announce the FDA clearance of the MeRT® System for adults with PTSD — an important milestone in the continued advancement of personalized, EEG-guided neuromodulation.
PTSD affects millions of individuals and remains one of the most complex challenges in mental healthcare. Despite growing awareness and expanding treatment options, many individuals continue searching for approaches that align more closely with their individual needs.
The FDA clearance of MeRT for PTSD represents an important step toward integrating objective measurements of brain activity into neuromodulation workflows.
Mental healthcare has historically relied heavily on symptom-based evaluation and standardized treatment pathways. Advances in neuroscience, however, continue to expand understanding of how measurable patterns of brain activity may relate to neuropsychiatric conditions such as PTSD.
MeRT uses EEG-derived brain activity measurements to guide individualized stimulation parameters within FDA-cleared TMS frameworks.
This clearance reflects years of clinical research, collaboration, and scientific evaluation focused on advancing precision approaches in neuromodulation.
The FDA clearance of MeRT for PTSD represents more than a company milestone — it reflects continued momentum toward more personalized and biomarker-informed approaches in mental healthcare.
Wave Neuroscience remains committed to supporting ongoing research, clinician education, and responsible innovation in the field of brain-guided neuromodulation.
